Pfizer's stock possession is going through a phase. The
stock turnaround has stalled due to missteps over its Covid/Flu management and its market performance has been unpredictable. Big investors like
iA Global Asset Management and billionaires are increasing their stocks' position, indicating potential attraction towards Pfizer. Meanwhile, it's struggling with its pricing rates and continually being compared to its competitors like
Eli Lilly,
Merck and
Alnylam. However, it’s not all bad news: it unveiled a
Direct-to-Customer (DTC) service for selling drugs and launched a direct sales website for vaccines and medicines offering some hope. Additionally, Pfizer is developing an obesity pill, and also, the
company's diabetes stock is attracting hedge fund interest. It is further indicated that its
dividend yield is impressive, and it's being dubbed as a potentially affordable stock under $50. On the slightly negative end, the stock has seen a 5.9% downfall since its earnings report, while ongoing market fluctuations have also affected their performance.
Pfizer Stocks News Analytics from Wed, 13 Dec 2023 08:00:00 GMT to Sun, 01 Sep 2024 23:43:44 GMT -
Rating -2
- Innovation 3
- Information 6
- Rumor -2
